Free Trial

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Vertex Pharmaceuticals logo
$407.37 -0.42 (-0.10%)
Closing price 10/13/2025 04:00 PM Eastern
Extended Trading
$406.17 -1.20 (-0.29%)
As of 06:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
12
Buy
17

Based on 29 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 29 analysts, 12 have given a hold rating, 16 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$494.38
21.36% Upside
According to the 29 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $494.38. The highest price target for VRTX is $575.00, while the lowest price target for VRTX is $405.00. The average price target represents a forecasted upside of 21.36% from the current price of $407.37.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRTX Analyst Ratings Over Time

TypeCurrent Forecast
10/14/24 to 10/14/25
1 Month Ago
9/14/24 to 9/14/25
3 Months Ago
7/16/24 to 7/16/25
1 Year Ago
10/15/23 to 10/14/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
14 Buy rating(s)
13 Buy rating(s)
17 Buy rating(s)
Hold
12 Hold rating(s)
13 Hold rating(s)
14 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$494.38$496.05$511.71$489.30
Forecasted Upside21.36% Upside25.73% Upside8.98% Upside0.92% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Vertex Pharmaceuticals Stock vs. The Competition

TypeVertex PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.62
2.33
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside21.36% Upside1,030.14% Upside14.04% Upside
News Sentiment Rating
Positive News

See Recent VRTX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/10/2025Morgan Stanley
3 of 5 stars
Matthew Harrison
Matthew Harrison
4 of 5 stars
Lower TargetEqual Weight$439.00 ➝ $438.00+6.15%
10/8/2025JPMorgan Chase & Co.
2 of 5 stars
Jessica Fye
Jessica Fye
Not Rated
Boost TargetOverweight$517.00 ➝ $530.00+26.34%
10/8/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C+)
10/2/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$550.00 ➝ $575.00+40.80%
9/25/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldStrong-Buy
9/25/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$458.00 ➝ $456.00+21.08%
9/11/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$510.00 ➝ $475.00+21.55%
9/2/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform
8/6/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetHold$424.00 ➝ $411.00+6.45%
8/6/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$558.00 ➝ $546.00+40.91%
8/6/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual WeightOverweight$460.00+22.67%
8/5/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetSector Perform$442.00 ➝ $438.00+11.47%
8/5/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetBuy$520.00 ➝ $490.00+24.70%
8/5/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetSector Perform$430.00 ➝ $405.00+3.86%
8/5/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetBuy$582.00 ➝ $553.00+37.88%
8/5/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetOutperform$557.00 ➝ $530.00+12.22%
8/5/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$535.00 ➝ $485.00+2.70%
8/5/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetHold$494.00 ➝ $455.00-3.66%
8/5/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$550.00 ➝ $478.00+1.21%
5/23/2025Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
5/7/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperformPeer Perform
5/6/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
5/6/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
5/6/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
3/31/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$555.00 ➝ $567.00+15.08%
2/11/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$435.00 ➝ $467.00+1.35%
1/27/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOverweight$535.00 ➝ $533.00+20.72%
12/19/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperformMarket Perform
12/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldBuy$500.00 ➝ $550.00+19.02%
7/23/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$450.00 ➝ $500.00+1.60%
6/27/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$545.00+14.98%
6/17/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$465.00 ➝ $550.00+15.48%
2/2/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeOutperformMarket Perform
1/31/2024Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeNeutralUnderperform$325.00-25.27%
1/31/2024Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:30 AM ET.


Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 11, 2025. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

  • The company recently reported earnings per share (EPS) of $4.52, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • Vertex Pharmaceuticals Incorporated achieved a revenue of $2.94 billion for the quarter, surpassing estimates, showcasing its robust market position and demand for its products.
  • The stock price is currently around $389.68, reflecting a significant investment by insiders, which can be a positive signal about the company's future prospects.
  • With a net margin of 31.86%, the company demonstrates effective cost management and profitability, which can lead to higher returns for investors.
  • Analysts forecast an EPS of 15.63 for the current fiscal year, suggesting continued growth and profitability, making it an attractive option for investors looking for growth stocks.

Vertex Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

  • Despite recent successes, the company has a history of fluctuating earnings, including a loss of ($12.83) EPS during the same quarter last year, which may raise concerns about consistency.
  • Insider ownership is relatively low at 0.20%, which could indicate less alignment between management and shareholder interests.
  • Some analysts have downgraded the stock from "strong-buy" to "buy," suggesting a potential decrease in investor confidence and future performance expectations.
  • Target prices set by analysts vary significantly, with some estimates dropping, indicating uncertainty in the stock's future valuation.
  • The competitive landscape in the biotechnology sector is intense, and any setbacks in product development or regulatory approvals could negatively impact the company's stock performance.

VRTX Forecast - Frequently Asked Questions

According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $494.38, with a high forecast of $575.00 and a low forecast of $405.00.

29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 12 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VRTX shares.

According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 21.36% based on their 12-month stock forecasts.

Over the previous 90 days, Vertex Pharmaceuticals's stock had 3 upgrades by analysts.

Analysts like Vertex Pharmaceuticals more than other "medical" companies. The consensus rating for Vertex Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how VRTX compares to other companies.


This page (NASDAQ:VRTX) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners